RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/25519054http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/25519054http://www.w3.org/2000/01/rdf-schema#comment"MicroRNAs (miRNAs) present frequently altered expression in urologic cancers including prostate, bladder, and kidney cancer. The altered expression of miR-223 has been reported in cancers and other diseases in recent researches. MiR-223 is up-regulated in systemic lupus erythematosus and rheumatoid arthritis. In neoplastic diseases, miR-223 is proved to be up-expressed in plasma or serum and cancer tissues compared with normal tissues in pancreatic cancer, gastric cancer, et al. However, whether altered expression of miR-223 is associated with prostate cancer (PCa) and what it is potential functions in PCa remained unveiled. In this study, we firstly found miR-223-3p were up-regulated in prostate cancer tissues and then we study functional role of miR-223-3p in PCa using DU145, PC3 and LNCaP cell lines. Our data suggested that miR-223-3p might target gene SEPT6 and promoted the biological behavior of prostate cancer. Notably, we found increasing SEPT6 expression might reverse the biological activity induced by miR-223-3p, which might be a potential therapeutic target for PCa."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.org/dc/terms/identifier"doi:10.1038/srep07546"xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Dong Z."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Gao Y."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Liu Z."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Wei Y."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Wang Y."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Yang J."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Wang Z."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Wu H."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Yan B."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Zhou K."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Yin Z."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Yi L."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Zhong Z."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/author"Ou-yang S."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/date"2014"xsd:gYear
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/name"Sci Rep"xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/pages"7546"xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/title"MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer."xsd:string
http://purl.uniprot.org/citations/25519054http://purl.uniprot.org/core/volume"4"xsd:string
http://purl.uniprot.org/citations/25519054http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/25519054
http://purl.uniprot.org/citations/25519054http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/25519054
http://purl.uniprot.org/uniprot/#_Q14141-mappedCitation-25519054http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/25519054